ORGS - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Orgenesis Inc.

High debt leverage and a lack of liquidity are weakening the competitive position of Orgenesis Inc. (ORGS). The year-over-year sales dynamics for the last 12 months (TTM) illustrate these challenges, where the value of -5.30 captures the metric level. Orgenesis Inc. (ORGS) aims to capture the med-IT market through B2B implementation of gene therapy software, relying on decentralized node logistics located near clinics to ensure the preservation of live cells.
פילוחי נתונים אנליטיים מרוכזים עבור Orgenesis Corp (ORGS)

For Orgenesis Inc. (ORGS), the trailing twelve-month (TTM) revenue dynamics reflect the expansion rate of its mobile laboratory network and the effectiveness of B2B customer retention under strict FDA oversight. By analyzing the year-over-year sales trajectory (TTM), investors can filter out market noise, where an upward trend confirms the scaling of the biotech ecosystem, while a decline signals stagnation in the business's fundamental development.